APDM WEARABLE TECHNOLOGIES, INC.

Clario is a leading provider of clinical trial endpoint data solutions — spanning cardiac safety, eCOA, medical imaging, respiratory, precision motion, and clinical adjudication — serving pharmaceutical, biotech, and CRO customers across every phase of drug development. Clario integrates endpoint data from devices, sites, and patients, enabling customers to digitally collect, manage, and analyze clinical evidence, with its platform supporting approximately 70% of FDA and EMA novel drug approvals over the past decade. Founded in 1999 as eResearchTechnology (ERT), Clario employs approximately 4,000 people globally. Thermo Fisher Scientific (NYSE: TMO) completed its acquisition of Clario on March 24, 2026, for $8.875 billion in cash plus potential additional earnout payments. Clario now operates as part of Thermo Fisher's Laboratory Products and Biopharma Services segment.

From the manufacturer's own website. Source